Despite their physiological roles, Müller glial cells are involved directly or indirectly in retinal disease pathogenesis and are an interesting target for therapeutic approaches for retinal diseases and regeneration such as CRB1 inherited retinal dystrophies. In this study, we characterized the efficiency of adeno-associated virus (AAV) capsid variants and different promoters to drive protein expression in Müller glial cells. ShH10Y and AAV9 were the most powerful capsids to infect mouse Müller glial cells. Retinaldehydebinding protein 1 (RLBP1) promoter was the most powerful promoter to transduce Müller glial cells. ShH10Y capsids and RLBP1 promoter targeted human Müller glial cells in vitro. We also developed and tested smaller promoters to express the large CRB1 gene via AAV vectors. Minimal cytomegalovirus (CMV) promoter allowed expression of full-length CRB1 protein in Müller glial cells. In summary, ShH10Y and AAV9 capsids, and RLBP1 or minimal CMV promoters are of interest as specific tools to target and express in mouse or human Müller glial cells. and RLBP1 Müller glial cell-specific promoters and engineered small minimal CD44 and CMV promoters to efficiently transduce Müller glial cells. We showed that ShH10Y via the intravitreal route and AAV9 via the subretinal route showed the best efficiency to transduce mouse Müller glial cells. CD44 and CMV promoters using ShH10Y capsids drove expression mainly in Müller glial cells, whereas the RLBP1 promoter mediated high expression specifically in Müller glial cells via the intravitreal route. AAV ShH10 and ShH10Y capsids with CMV or RLBP1 promoters mediate green fluorescent protein (GFP) expression in human Müller glial cells in vitro. Finally, we showed that only a small minimal CMV promoter and the small human G protein-coupled receptor kinase 1 (GRK1) promoter drive efficient expression of fulllength CRB1 protein in Müller glial or photoreceptors, respectively.
INTRODUCTION
During vertebrate retina development, from a common pool of retinal progenitor cells, six types of neurons and the Müller glial cells are generated. While their somas reside in the inner nuclear layer, Müller glial cells extend from their basal end feet facing the vitreous and forming the inner limiting membrane, to their apical microvilli in the subretinal space. They provide structural, nutritional, homeostatic, osmotic, metabolic, and growth factor support to all six types of neurons and interact with photoreceptor cells to establish adherens junctions at the outer limiting membrane. 1, 2 Despite their active role in the retinal signaling activity of neurons, Müller glial cells interact with the retinal blood vessels that participate in the establishment of the blood-retina barrier and regulate the retinal blood flow and are directly involved in the vision cycle of photopigments via the expression of the retinaldehyde-binding protein 1 (RLBP1). 1, 3 In the last two decades, Müller glial cells are shown to reside as potential retinal progenitor cells in the adult retina. 2, 4, 5 In zebrafish and chick, following injury, the Müller glial cells can dedifferentiate, proliferate, and give rise to the six types of neurons to replace the lost neurons in the damaged area, whereas in mammals, this potency is limited.
Müller glial cells play a neuroprotective and/or deleterious role in response to retinal injury, stress, or degeneration via active gliosis. 1 Many diseases such as diabetes, macular edema, proliferative vitreoretinopathies, or ischemia directly affect their physiology leading to swelling, to proliferation, and eventually to death of the Müller glial cells. Most of the genes causing inherited retinal dystrophies affect mainly photoreceptor cells, but also Müller glial and retinal pigment epithelium (RPE). Mutations in the RLBP1 and CRB1 genes expressed in Müller glial cells have been reported to cause retinal dystrophies. [6] [7] [8] [9] [10] [11] Therefore, Müller glial cells are an interesting target for new therapeutic approaches for retinal disease and regeneration in vivo.
Adeno-associated virus (AAV) vectors are the most powerful and safest viral vectors as over 20 approved clinical trials are ongoing in humans and also for retinal gene transfer. 12 Previously, we and others have shown that AAV6 capsids are the most efficient variant to drive expression in murine Müller glial cells via the intravitreal route. 13, 14 AAV capsids have been engineered to enhance glial gene delivery, and the AAV6-derived capsid variant ShH10 was shown to transduce mainly Müller glial cells in the rat retina. 15, 16 ShH10 viral vector-mediatedspecific secretion of the growth factor glial cell-derived neurotrophic factor from Müller glial cells delays photoreceptor degeneration in a rat model of retinal dystrophy. 17 Selective loss of Müller glial cells using an optogenetic photo-inducible toxic protein leads to structural and retinal activity impairment in wild-type mice. 18 Using lentiviral vectors, several ubiquitous (cytomegalovirus (CMV), CAG) and specific (CD44, glial fibrillary acidic protein) promoters have been tested in rat retinas, and the highest expression level in Müller glial cells was obtained with a CD44 promoter. 19 Using AAV vectors, the glial fibrillary acidic protein promoter showed restricted expression in ciliary neurotrophic factor-activated Müller glial cells, 14 and engineered glial fibrillary acidic protein promoter with several hypoxia-responsive elements has been developed to induce expression under hypoxic condition. 20 So far, no strong, constitutive, and Müller glial cell-specific promoter has been reported using AAV vectors.
In this study, we analyzed the transduction profile of AAV6, ShH10, ShH10Y, and AAV9 via the intravitreal and subretinal route in mouse retinas and human retina cultures. We tested the potency of CD44 and RLBP1 Müller glial cell-specific promoters and engineered small minimal CD44 and CMV promoters to efficiently transduce Müller glial cells. We showed that ShH10Y via the intravitreal route and AAV9 via the subretinal route showed the best efficiency to transduce mouse Müller glial cells. CD44 and CMV promoters using ShH10Y capsids drove expression mainly in Müller glial cells, whereas the RLBP1 promoter mediated high expression specifically in Müller glial cells via the intravitreal route. AAV ShH10 and ShH10Y capsids with CMV or RLBP1 promoters mediate green fluorescent protein (GFP) expression in human Müller glial cells in vitro. Finally, we showed that only a small minimal CMV promoter and the small human G protein-coupled receptor kinase 1 (GRK1) promoter drive efficient expression of fulllength CRB1 protein in Müller glial or photoreceptors, respectively.
ReSUlTS

ShH10Y and AAV9 capsids efficiently transduce mouse Müller glial cells
We studied the transduction and expression profiles of AAV6, ShH10, and ShH10Y, (ShH10Y carries an additional tyrosine to phenylalanine mutation to enhance its transduction efficiency). 21 We intravitreally injected Crb1 −/− retinas with 10 8 , 10
, 10 10 genome copies (gc) of CMV-GFP transgene packaged in the different AAV serotypes. We analyzed the GFP expression by scanning laser ophthalmoscopy (SLO) and immunohistochemistry using cell typespecific immunomarkers in retinal sections. At 10 8 gc, the ShH10Y variant showed enhanced ability to transduce Müller glial cells relative to the unmodified ShH10 and AAV6 capsids (49 ± 6, 24 ± 3, and 21 ± 3%, respectively; Figure 1d ), the total number of GFP-positive cells per millimeter was not different (28 ± 4, 29 ± 6, and 26 ± 3%, respectively). At one log unit higher titer (10 9 gc), ShH10Y also showed the highest percentage of transduced mouse Müller glial cells, whereas ShH10 and AAV6 transduced less efficiently (66 ± 4, 23 ± 2, and 17 ± 6%, respectively; Figure 1e ), the total number of infected cells per millimeter was not different (49 ± 2, 47 ± 10, and 51 ± 2, respectively). At 10 10 gc, the cell types infected by AAV6 were primarily around the blood vessels as shown previously, 14 whereas both ShH10 and ShH10Y showed a broader transduction pattern (Figure 1a , and (f) 10 10 gc showed that ShH10Y is the most powerful capsid to transduce mouse Müller glial cells even at low doses. Data are presented as mean ± SEM and n = 3/AAV/dose. **P < 0.01, ***P < 0.001. Bar = 50 µm (a-c). AAV, adeno-associated virus; CMV, cytomegalovirus; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; PRC, photoreceptor cell; RPE, retinal pigment epithelium. The AAV9 capsid has been shown to efficiently transduce many retinal cells including photoreceptors and Müller glial cells via the subretinal route. 22, 23 Intravitreal injection of AAV9-CMV-GFP resulted in transduction of few ganglion cells (data not shown). We compared the subretinal transduction efficiency of AAV9 with AAV6, 14 ShH10, and ShH10Y ( Figure 2 ). The percentage of GFP-positive Müller glial cells produced by AAV9 and ShH10Y injection was higher and similar (30 ± 2 and 26 ± 6%, respectively) relative to AAV6 and ShH10 vectors (11 ± 1 and 7 ± 3%, respectively). However, AAV9 transduced more mouse retinal cells than ShH10Y (483 ± 171 versus 100 ± 33 GFP-positive cells per millimeter). In summary, AAV9 and ShH10Y are potent capsids to transduce mouse Müller glial cells via the subretinal route.
The ShH10Y-CD44 promoter drives low levels of expression in Müller glial cells The 1.8-kb mouse full-length CD44 promoter 24 was subcloned into the AAV plasmid and packaged in ShH10Y capsids. Three weeks after intravitreal injection of ShH10Y containing the full-length CD44-GFP, SLO imaging showed weak GFP expression along blood vessels with occasional brighter spots of GFP expression ( Figure  3a) . Transverse retinal sections showed weak GFP expression in the inner nuclear and ganglion cell layers. Cell-specific markers verified that GFP-positive cells were primarily Müller glial cells (Figure 3b,c) , with a few GFP-positive amacrine, ganglion cells, or astrocytes (Figure 3c ). When injected into the subretinal space, ShH10Y fulllength CD44-GFP vectors generated low-level GFP expression primarily in Müller glial cells but also in RPE and photoreceptor cells at the site of injection (see Supplementary Figure S1a ). Interestingly, we found increased GFP expression in areas associated with gliosis, ectopic localization of Müller glial nuclei, and presence of activated microglia cells (see Supplementary Figure S1b Small promoters are required to fit large genes such as full-length 4.2-kb CRB1 complementary DNA (cDNA) within the 4.7-kb AAV packaging limit to allow efficient packaging and expression. 10, 25 It was shown that a 0.4-kb CD44 promoter was sufficient to drive significant levels of gene expression in vascular smooth muscle cells. 26 Therefore, we tested the 0.4-kb minimal CD44 promoter and analyzed its pattern of expression in the retina. Three weeks after intravitreal injection of ShH10Y-minimal CD44-GFP, no GFP was visible on SLO imaging (Figure 3e ). Immunohistochemistry against GFP showed few GFPpositive cells per eye and GFP expression just above detection levels. Most of the GFP-positive cells were Müller glial cells (Figure 3f ,g). Truncation of the promoter did not affect the transduction profile of the promoter but drastically reduced the number of GFP-positive cells per millimeter (113 ± 11 for full-length CD44 versus 2 ± 1 for minimal CD44; Figure 3h ). We conclude that the AAV-minimal or full-length CD44 promoters are not appropriate to express CRB1 protein.
The ShH10Y-RLBP1 promoter mediates high levels of expression in Müller glia cells A 2.8-kb fragment of the human RLBP1 promoter, which is highly conserved between human and mice, 27 was synthesized and subcloned into an AAV2 plasmid. At 3 weeks postintravitreal injection of ShH10Y-RLBP1-GFP, SLO revealed strong GFP expression mainly along the blood vessels and around the optic nerve ( Figure 4a ). The RLBP1 promoter restricts expression to Müller glial cells, which was confirmed by specific immunomarkers (Figure 4b When injected subretinally, AAV2/9-minimal CMV-GFP showed many GFP-positive cells similar to the full-length CMV promoter (see Supplementary Figure S2a ) at 3 weeks postinjection. However, in contrast to the full-length CMV promoter, the minimal CMV promoter mediated decreased levels of GFP expression in the RPE (Figure 2c and Supplementary Figure S2a) . The AAV-minimal CMV vector transduced Müller glial cells (see Supplementary Figure S2b ), cone (see Supplementary Figure  S2e ) and rod photoreceptor cells (see Supplementary Figure S2e) , and only few bipolar (see Supplementary Figure S2c ) and amacrine cells (see Supplementary Figure S2d ). The ShH10Y-minimal CMV vector showed a reduced number of GFP-positive RPE cells (5 ± 2% for minimal CMV versus 12 ± 1% for full-length CMV; see Supplementary Figure S2f ).
Minimal promoters showed efficient expression of full-length CRB1
Several studies have demonstrated that AAV viruses have a limited packaging capacity of 4.7-5.2 kb of transgenic DNA depending on the serotype, larger transgenes showed 3′ or 5′ deletions and/ or significant reductions in the titer. [31] [32] [33] [34] We attempted to express a full-length CRB1 cDNA (4.2 kb) with a 5.23-kb AAV vector that included a full-length CMV promoter, short synthetic polyadenylation sequences, and AAV2 inverted terminal repeat sequences. We found that CRB1 protein was barely detectable upon subretinal injection of AAV2/5-CMV-hCRB1 vector and was undetectable from CMV-hCRB1 vector packaged with AAV6, ShH10, or ShH10Y capsids (see Supplementary Figure S3a) . However, the human CRB1 transcript was detected in retinas transduced with AAV6, ShH10, or ShH10Y capsids (see Supplementary Figure S3b ). Using human embryonic kidney 293T cell lines, we showed that CRB1 and GFP proteins were efficiently expressed upon transfection and infection, respectively, whereas almost no CRB1 protein was detectable after infection (see Supplementary Figure S3c) . Therefore, we suggest that the use of full-length CMV promoter and CRB1 gene exceeds the AAV packaging limitation. In order to obtain efficient and persistent expression of a functional CRB1 protein in Müller glial cells, 35 the AAV vector insert has to be within the 4.7-to 5.2-kb packaging limit, and this can be achieved by either shortening the promoter or the CRB1 gene. The minimal CMV (Figure 7 and Supplementary Figure S2 ) and the human GRK1 promoter 36 (see Supplementary Figure S4a -b) were used to drive the expression of the full-length CRB1 cDNA in Müller glial cells, photoreceptors, and RPE cells and only cones and rods, respectively. The full-length CMV promoter and an engineered 0.5-kb human rhodopsin promoter (see Supplementary Figure S4c -d) were used to express a naturally occurring 3.9-kb short variant of the CRB1 cDNA, called CRB1Δ in Müller glial cells, photoreceptors and RPE cells and only rods, respectively. This transcript variant carries an in-frame deletion of exons 3-4 and is expressed in the human retina. 37 All four AAV-CRB1 expression vectors mediated detectable levels of CRB1 protein in Crb1 −/− retinas and expression at the subapical region near physiological levels ( Figure 8 ). Using AAV2/9-minimal CMV-CRB1, full-length CRB1 protein was mainly found at the subapical region of Müller glia cells and photoreceptors and at the apical membrane of RPE cells (Figure 8c ). Using AAV2/9-hGRK1-CRB1, full-length CRB1 protein was expressed in rod and cone photoreceptors and was mainly found at the subapical region or in inner segments and minimally in their somata (Figure 8d ). Using AAV2/9-CMV-CRB1Δ, the short CRB1Δ protein was mainly found at the subapical region of Müller glia cells and photoreceptors but also at a low level of expression in the soma of photoreceptors and in RPE (Figure 8e ). Using AAV2/9-RHO-CRB1Δ, the short CRB1Δ protein was specifically expressed in rod photoreceptors but likely overexpressed as the protein localized at the subapical region, in their inner segments and somata (Figure 8f ). However, using CRB1 or CRB1Δ vectors, we found some potential toxicity associated with high levels of CRB1 around the site of injection (see Supplementary Figure S3d ShH10, a capsid variant derived from AAV6, showed a significant variation in its transduction profile between rat and mouse retinas. Whereas up to 94% of the GFP-positive cells were Müller glial cells in rat retinas, 16 only 39% were Müller glial cells in mouse retinas at the highest vector doses. Differences in transduction efficiency and tropism of the native AAV6 had been previously reported between rat and mouse retinas, and this difference may be due to differences in the mechanical barrier function of inner limiting membrane between the species. 14, 16, 38 In rat, AAV6 transduces few ganglion or inner nuclear layer cells, 16 whereas in mice, AAV6 capsids efficiently infect the retina along the major retinal blood vessels where the inner limiting membrane is thought to be thinner. 14 The receptor binding characteristics of AAV6 and AAV6-derived capsids may also be highly dependent on the protein composition of the inner limiting membrane barrier. Another reason that may explain the difference in tropism observed with application of ShH10 vectors in mouse is that this mutant was initially selected from a library of millions of variants using primary astrocytes from human adult cortex 15 and subsequently tested for its transduction characteristics on rat Müller glial cells in vivo. 16 The ShH10 variant with the additional Y445F mutation, which reduces the number of exposed tyrosine residues on the AAV surface and resultant ubiquitination and proteasome degradation, showed a threefold increase in efficiency for transduction of mouse Müller glial cells in comparison to AAV6, which was seen at low and high titers. ShH10 and ShH10Y capsids were able to infect Müller glial cells in human retina in culture similarly to AAV6 as described previously. 14 The CD44 promoter, which has been shown to efficiently drive gene expression in Müller glial cells using a lentiviral vector in rats, 19 showed low levels of gene expression that was not restricted to Müller glial cells in mouse retina. Truncation of the CD44 promoter decreased its basal activity, a finding that is in contrast to the observations in vascular smooth muscle. 26 One interesting finding is that in the degenerating areas due to the Crb1 −/− phenotype and/or injury from the subretinal injection, increased transduction and/or expression was observed in areas with gliosis and activated microglia cells. It has been previously described that the CD44 promoter is upregulated in arterial wall injury in vivo and can be activated by the proinflammatory cytokine interleukin 1β. 39, 40 We speculate that similar to smooth muscle cells, retinal injury and possibly proinflammatory cytokines (activated microglial and Müller glial cells) might increase the CD44 promoter activity in retina. As the injury-responsive element, activating protein 1 is conserved in the minimal CD44 promoter, 26 an interesting in vivo study using the full-length and the minimal CD44 promoters, and testing injection of different cytokines might reveal that the CD44 promoter in the retina reacts similar as in smooth muscle cells. Therefore, the ShH10Y-CD44-GFP virus might be an interesting tool to study inflammatory processes in the retina.
The human RLBP1 promoter fragment showed a similar pattern of expression as the endogenous RLBP1 protein, restricted to RPE and Müller glial cells. However, this promoter is large (2.85 kb) and complex as the initiation codon is in exon 3.
27,41 A shortened RLBP1 promoter might be useful to obtain expression restricted to Müller glial cells and to package large genes such as CRB1. Several studies demonstrated that AAV viruses have a limited packaging and expression capacity of 4.7-5.2 kb of transgenic DNA depending on the serotype. [31] [32] [33] [34] Here, we showed that the CRB1 gene can be expressed in retinal cells using AAV vectors with short promoters such as a minimal CMV promoter or the human GRK1 promoter.
Over the last decades, Müller glial cells became an interesting target for therapeutic and regeneration studies. In this study, we characterized and provided new tools, which are combinations of ShH10Y capsids, RLBP1, or a minimal CMV promoter, to target mouse and human Müller glial cells and express relatively large genes such as CRB1.
MATeRIAlS AND MeTHODS
Generation and purification of the viral vectors
The pAAV2-GFP plasmids were generated previously 14, 42 and consist of the flanking inverted terminal repeats of AAV2, the CMV promoter, the eGFP cDNA, the woodchuck posttranscriptional regulatory element, and the SV40 polyadenylation sequence. The pAAV2-CRB1 plasmids consist of the flanking inverted terminal repeats of AAV2, the CMV promoter, the CRB1 cDNA or codon optimized CRB1 cDNA (pAAV2-coCRB1), and a 48-bp synthetic polyadenylation sequence. The murine full-length 1.8-kb 24 and the minimal 0.36-kb 26 CD44 promoters were amplified by polymerase chain reaction from CD44prm-pXP2 and subcloned using Not I and Xho I in pAAV2-GFP vectors. The human 2.85-kb RLBP1, 27 formally cellular retinaldehyde-binding protein (CRALBP), was synthesized at GenScript (Piscataway, NJ) with eGFP cDNA, the woodchuck posttranscriptional regulatory element and the bovine growth hormone polyadenylation sequence and subcloned in pAAV2 via Bgl II restriction sites. The minimal 0.26-kb CMV was assembled (sequence in Supplementary Materials and Methods) according to the minimal promoter and enhancer sequences previously described, 29, 30 synthesized at GenScript and subcloned using Spe I and Xho I restriction sites in pAAV2-GFP and pAAV2-coCRB1 vectors. The 0.31-kb human GRK1 promoter 36 was synthesized at GenScript and subcloned using Spe I and Xho I restriction sites in pAAV2-GFP vectors and pAAV2-coCRB1 vectors. pAAV2-coCRB1Δ were obtained by deletion of exons 3-4 (0.32 kb) of codon optimized CRB1 cDNA. A 0.52-kb human rhodopsin promoter was designed, synthesized at GenScript, and subcloned using Spe I and Xho I restriction sites in pAAV2-GFP vectors and pAAV2-coCRB1Δ vectors.
AAV stocks were generated and purified as previously described. 14, 16 Briefly, pAAV2-GFP transgene plasmids were cotransfected with the AAV2/6 helper plasmid pDP6 (Plasmid Factory, Bielefeld, Germany) or pHelper and pXX2-ShH10 or pXX2-ShH10Y445F 16, 17 or pAAV9 capsid plasmid into human embryonic kidney 293T cells to generate AAV2/6, AAV2/9, AAV2/ShH10, and AAV2/ShH10Y viral particles. After DNase treatment, the lysates were ultracentrifuged onto an iodixanol density gradient (Sigma, St. Louis, MO). All viral titers were determined by quantitative polymerase chain reaction and all viral stocks with titers around 1 × 10 13 gc per ml were stored at −80 °C. 11 were maintained on a 50% C57BL/6J and 50% 129/Ola genetic background and on a 12-hour day/night cycle and supplied with food and water ad libitum. One-month-old Crb1 −/− mice were anesthetized with 100 mg/kg ketamine and 5 mg/kg xylazine intraperitoneally, and the iris was dilated using phenylephrine (0.5% in saline). The mice were injected either subretinally or intravitreally as previously described , and 10 10 gc of each AAV. After injection, eyes were treated with chloramphenicol, and mice were kept on a heating pad until they fully recovered from anesthesia.
Scanning laser ophthalmoscopy
Three weeks after injection of the viral vector, the mice were anesthetized with 100 mg/kg ketamine and 5 mg/kg xylazine intraperitoneally, and the iris was dilated using phenylephrine (0.5% in saline). In vivo SLO was performed using the Heidelberg Retina Angiograph 2 (HRA 2; Heidelberg Engineering, Heidelberg, Germany) at 830 nm for infrared-native fundus images and at 488 nm for GFP fluorescence images with a barrier filter at 500 nm.
Immunohistochemical analysis
The anaesthetized mice were sacrificed by cervical dislocation immediately after imaging. Enucleated eyes were fixed for 30 minutes in 4% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.4) and cryoprotected by subsequent incubations of 30 minutes in 5 and 30% sucrose in PBS. The eyes were embedded in Tissue-Tek (Sakura, Zoeterwoude, The Netherlands), frozen, and stored at −20 °C. Sections of 7-10 µm were generated using a Leica CM3050 cryostat (Leica Microsystems, Rijswijk, The Netherlands) and were either enclosed immediately in Vectashield DAPIHardSet mounting media (Vector Laboratories, Amsterdam, The Netherlands) or used for immunohistochemical analysis. Sections for immunohistochemistry were blocked for 1 hour in 10% normal goat serum, 0.4% Triton X-100, and 1% bovine serum albumin in PBS, incubated in a moist chamber overnight (at 4 °C) or blocked for 2 hours at room temperature with appropriate primary antibodies (see Supplementary Table S1 ) diluted in 0.3% normal goat serum, 0.4 % Triton X-100, and 1% bovine serum albumin in PBS. After rinsing in PBS, the sections were incubated for 1 hour with Cy3-conjugated goat secondary antibodies anti-mouse or anti-rabbit and rinsed in PBS again. Sections were mounted in Vectashield HardSet 4' ,6-diamidino-2-phenylindole (DAPI) mounting media. The GFP and the cyanine3 signal were visualized with a Leica DMRE fluorescence microscope for overview pictures and confocal SP5 (Leica Microsystems) for immunohistochemical analysis.
Quantification of the GFP-positive cells
Transduction profiles were analyzed by counting individual GFP-positive somata, defined by their typical morphology and/or with colabeling with specific marker for each cell type (see Supplementary Table S1 ) on the total number of GFP-positive cells. Müller glial cells have a well-defined morphology as they span the entire retina reaching the outer and inner limiting membranes, and they display lozenge-shaped nuclei in the middle of the inner nuclear layer. At least five different sections from each eye from three to four retinas were counted. The number of GFP-positive cells for each cell type was divided by the total number of cells to obtain the percentage of transduced cells.
In vitro transduction of the human retina
This study was performed in agreement with the declaration of Helsinki on the use of human material for research. Postmortem human donor eyes were acquired from the Euro Cornea Bank and were processed within 48 hours after death. Retinas from the middle periphery were dissected from the eye and cultured for 7 days with the photoreceptor layer facing down as previously described.
14 Retinas were injected under the lifted inner limiting membrane with 1 μl of 1 × 10 10 gc of AAV2/ShH10-CMV-GFP, AAV2/ShH10Y-CMV-GFP, and AAV2/ShH10Y-RLBP1-GFP. After 1 week, the retinas were fixed for 30 minutes in 4% paraformaldehyde in PBS (pH 7.4), cryoprotected by subsequent incubations of 30 minutes in 5 and 30% sucrose in PBS, and frozen in Tissue-Tek. Sections of 10 µm were generated with a Leica CM3050 cryostat (Leica Microsystems) and were enclosed immediately in Vectashield DAPI HardSet mounting media (Vector Laboratories).
